Vaxart, Inc. (VXRT)
VXRT Stock Price Chart
Explore Vaxart, Inc. interactive price chart. Choose custom timeframes to analyze VXRT price movements and trends.
VXRT Company Profile
Discover essential business fundamentals and corporate details for Vaxart, Inc. (VXRT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
11 Dec 1981
Employees
105.00
Website
https://vaxart.comCEO
Steven Lo
Description
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.
VXRT Financial Timeline
Browse a chronological timeline of Vaxart, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 18 Mar 2026
Upcoming earnings on 12 Nov 2025
EPS estimate is -$0.07, while revenue estimate is $2.03M.
Earnings released on 13 Aug 2025
EPS came in at -$0.07 surpassing the estimated -$0.09 by +22.22%, while revenue for the quarter reached $39.73M , beating expectations by +1.71K%.
Earnings released on 13 May 2025
EPS came in at -$0.07 matching the estimated -$0.07, while revenue for the quarter reached $20.88M , beating expectations by +632.49%.
Earnings released on 20 Mar 2025
EPS came in at -$0.05 surpassing the estimated -$0.10 by +50.00%, while revenue for the quarter reached $15.19M , missing expectations by -26.88%.
Earnings released on 13 Nov 2024
EPS came in at -$0.06 surpassing the estimated -$0.10 by +40.00%, while revenue for the quarter reached $4.93M , missing expectations by -68.55%.
Earnings released on 8 Aug 2024
EPS came in at -$0.09 falling short of the estimated -$0.03 by -237.46%, while revenue for the quarter reached $6.40M , beating expectations by +6.30K%.
Earnings released on 13 May 2024
EPS came in at -$0.14 surpassing the estimated -$0.16 by +12.50%, while revenue for the quarter reached $2.18M , beating expectations by +172.63%.
Earnings released on 14 Mar 2024
EPS came in at -$0.12 surpassing the estimated -$0.15 by +20.00%, while revenue for the quarter reached $3.25M , beating expectations by +159.60%.
Earnings released on 2 Nov 2023
EPS came in at -$0.11 surpassing the estimated -$0.18 by +38.89%, while revenue for the quarter reached $446.00K , missing expectations by -59.45%.
Earnings released on 3 Aug 2023
EPS came in at -$0.16 surpassing the estimated -$0.19 by +15.79%, while revenue for the quarter reached $1.36M , beating expectations by +1.60K%.
Earnings released on 4 May 2023
EPS came in at -$0.19 matching the estimated -$0.19, while revenue for the quarter reached $675.00K , missing expectations by -15.63%.
Earnings released on 15 Mar 2023
EPS came in at -$0.18 surpassing the estimated -$0.22 by +18.18%, while revenue for the quarter reached $22.00K , missing expectations by -96.72%.
Earnings released on 8 Nov 2022
EPS came in at -$0.23 surpassing the estimated -$0.24 by +4.17%.
Earnings released on 8 Aug 2022
EPS came in at -$0.23 falling short of the estimated -$0.21 by -9.52%.
Earnings released on 9 May 2022
EPS came in at -$0.20 falling short of the estimated -$0.17 by -17.65%, while revenue for the quarter reached $85.00K , missing expectations by -32.00%.
Earnings released on 24 Feb 2022
EPS came in at -$0.17 matching the estimated -$0.17, while revenue for the quarter reached $74.00K , missing expectations by -59.51%.
Earnings released on 4 Nov 2021
EPS came in at -$0.14 surpassing the estimated -$0.15 by +6.67%, while revenue for the quarter reached $200.00K , missing expectations by -23.08%.
Earnings released on 5 Aug 2021
EPS came in at -$0.13 surpassing the estimated -$0.14 by +7.14%, while revenue for the quarter reached $112.00K , meeting expectations.
Earnings released on 3 May 2021
EPS came in at -$0.14 falling short of the estimated -$0.10 by -40.00%, while revenue for the quarter reached $506.00K , beating expectations by +1.01%.
Earnings released on 25 Feb 2021
EPS came in at -$0.13 falling short of the estimated -$0.08 by -62.50%, while revenue for the quarter reached $356.00K , beating expectations by +142.42%.
Earnings released on 12 Nov 2020
EPS came in at -$0.08 surpassing the estimated -$0.09 by +11.11%, while revenue for the quarter reached $265.00K , missing expectations by -10.00%.
VXRT Stock Performance
Access detailed VXRT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.